

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **INSIDE INFORMATION**

#### **COMPLETION OF THE CAPITAL INCREASE AGREEMENT**

Reference is made to the announcement of Jacobson Pharma Corporation Limited (the “Company”, together with its subsidiaries, the “Jacobson Group”) in relation to the entering of the Capital Increase Agreement and the Licensing Framework Agreement dated 20 December 2017. In this announcement, unless the context otherwise requires, capitalised terms shall have the same meaning as those defined in the said announcement.

This announcement is made by pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is pleased to announce that all conditions precedent under the Capital Increase Agreement have been fulfilled and that the Completion of the Capital Increase took place on 30 January 2018. Subsequent to the registration of the capital increase with the relevant PRC governmental bodies which is currently underway, Jacobson Group will become a registered shareholder holding 4,376,422 shares out of the registered capital of RMB449,312,666 with a total number of 449,312,666 issued shares of Shanghai Henlius.

#### **INFORMATION ON SHANGHAI HENLIUS**

Shanghai Henlius was established in 2010 as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (上海復星醫藥(集團)股份有限公司), with its principal business in the development, production and commercialization of monoclonal antibody biosimilar drugs, which covers a variety of therapeutic areas including oncology and autoimmune diseases. The Product is the second monoclonal antibody developed by Shanghai Henlius of general name: Recombinant Humanized Anti-Her2 Monoclonal Antibody Injection, which belongs to the

biosimilar version of Trastuzumab. In July 2015, Shanghai Henlius received CFDA approval for clinical trials of the Product for the indication of breast cancer. As of the date of this announcement, the Product for the indication of breast cancer has officially entered phase III trial. At the beginning of 2016, Shanghai Henlius received CFDA approval for clinical trials of the Product for the indication of gastric cancer.

**Shareholders and potential investors of the Company are reminded and should be aware that the commercialization of the Product under the Licensing Framework Agreement is subject to regulatory approval of relevant competent authorities. Shareholders and potential investors are advised to exercise caution when dealing in the Shares of the Company.**

By order of the Board  
**Jacobson Pharma Corporation Limited**  
**WU Lai King**  
*Company Secretary*

Hong Kong, 30 January 2018

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.*

\* *For identification purposes only*